Validation shows treatment strategies differ for breast cancer risk groups in postmenopausal ER+/HER2- patients, indicating benefits of AI models.
The Stratipath AI model performs similarly to the NHG system. Further prospective validation of the clinical benefits of differentiating Stratipath risk groups 2 and 3 in treatment strategies would be valuable.
No takes yet. Share an insight, caveat, or question.
Pouplier et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: